Site Editor
Jeremy S. Abramson, MD, MMSc
Jeremy S. Abramson, MD, MMSc
Posted: Friday, February 14, 2025
Previous studies have determined the clinical efficacy of combination therapy with the next-generation Bruton’s tyrosine kinase inhibitor zanubrutinib and the next-generation BCL2 inhibitor sonrotoclax in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a presentation given at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 1012). In the present study, this combined therapeutic approach was found to be well tolerated and safe for this patient population, explained Jacob D. Soumerai, MD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, and colleagues.
A total of 112 patients with treatment-naive CLL or SLL were recruited for the BGB-11417-101 study. Patients were randomly assigned to receive combination treatment with zanubrutinib plus either 160 mg (n = 51) or 320 mg (n = 61) of sonrotoclax. The dose of sonrotoclax was increased using a ramp-up approach to reduce the risk of tumor-lysis syndrome, which was assessed using the 2011 Howard criteria. Serum samples were collected every 24 weeks to assess clinical responses to treatment.
The study authors reported a 100% overall response rate, with similar complete response rates in both treatment groups. At the 24-week interval, the rate of undetectable measurable residual disease (MRD) in the blood was 61% and 77% for patients in the 160-mg group and 320-mg group, respectively. At the 48-week interval, the rate of undetectable MRD in the blood increased to 79% and 90%, respectively. Furthermore, neutropenia (41%), contusion (38%), COVID-19 infection (30%), and diarrhea (29%) were the most common treatment-related adverse events reported by patients.
Disclosure: For full disclosures of the study authors, visit ash.confex.com.
2024 ASH Annual Meeting & Exposition
